Abstracts tagged "Lupus"

Abstract Number: 393 • 2015 ACR/ARHP Annual Meeting
From Childhood to Adulthood: Identifying Latent Classes of Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus Patients
Lily Siok Hoon Lim¹, Eleanor Pullenayegum², Lillian Lim³, Dafna Gladman⁴, Brian Feldman⁵ and Earl Silverman⁶, ¹Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ³Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Although SLE patients are thought to follow different patterns of disease courses, no information is available about the longitudinal disease activity or the number…
Abstract Number: 799 • 2015 ACR/ARHP Annual Meeting
Transcriptional Profiling of Cutaneous Lupus Reveals Pronounced Changes in Keratinocyte and Myeloid Lineage Expressed Genes and Demonstrates Uniquely Regulated Interferon Pathways Between Rash Subtypes
Celine C. Berthier¹, Jasmine Stannard², Emily Myers³, William Swindell⁴, Lori Lowe⁴, Tamra J. Reed⁵, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁶, ¹Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ²Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, Georgetown University, Washington, DC, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus rashes can be substantial, disfiguring, and often refractory to usual lupus therapies. Phenotypic presentation and risk of systemic lupus manifestations differs by…
Abstract Number: 1752 • 2015 ACR/ARHP Annual Meeting
Characterization of Epitopes Identified with Cerebral Vasculature Injury
Melissa Butts¹, Jess Edison¹, Christopher Tracy¹, Brian Stout¹, Huazhen Chen² and Chantal Moratz², ¹Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Medicine, Uniformed Services University School of Health Sciences, Bethesda, MD
Background/Purpose: There is an association between natural antibodies, such as anti-phospholipid antibodies, and vasculature injury in stroke and in SLE models of systemic ischemic damage. …
Abstract Number: 2080 • 2015 ACR/ARHP Annual Meeting
Teaching Fellows in Lupus: Rheumatology Fellows Are Successful Educators in Improving Lupus Recognition By Frontline Healthcare Providers
Amy Caron¹, S. Sam Lim², Lexi Rene³, Diane Gross⁴, Maria Dall'Era⁵, Rosalind Ramsey-Goldman⁶ and Amanda Sammut⁷, ¹Lupus Research Institute, New York City, NY, ²Emory University School of Medicine, Atlanta, GA, ³Rollins School of Public Health, Emory University, Atlanta, GA, ⁴S.L.E. Lupus Foundation/Lupus Research Institute, New York, NY, ⁵University of California San Francisco School of Medicine, San Francisco, CA, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Columbia University Medical Center and Harlem Hospital Center, New York, NY
Background/Purpose: The heterogeneity and non-specific features of lupus may delay diagnosis. This delay can lead to accrual of organ damage and an increased risk of…
Abstract Number: 3222 • 2015 ACR/ARHP Annual Meeting
Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Chris Chamberlain¹, Murray Urowitz^2,3, Julie Soranson¹, Mark Watling¹, Peter Colman¹, Olivier Harari¹, Thomas Dorner⁴ and Falk Hiepe⁴, ¹UCB Pharma, Slough, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: CD40 ligand (CD40L) regulates interactions between T cells, B cells, and antigen presenting cells. Considerable evidence suggests CD40L blockade might provide an effective treatment…
Abstract Number: 397 • 2015 ACR/ARHP Annual Meeting
Longitudinal Observation of Psychological Factors and Health-Related Quality of Life in Childhood-Onset Lupus
Catherine Donnelly¹, Jordan T. Jones², Ji Li³, Natoshia Cunningham⁴, Susmita Kashikar-Zuck⁵ and Hermine I. Brunner², ¹Internal Medicine, University of Cincinnati, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Peking Union Medical College Hospital, Beijing, China, ⁴Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset Lupus (cSLE) is associated with decreased Health-related Quality of Life (HRQoL), and disease activity measures are often unrelated to overall perception of health. The…
Abstract Number: 804 • 2015 ACR/ARHP Annual Meeting
Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients
Yiu Tak Leung¹, Kathleen E. Sullivan², Kelly Maurer³, Li Song⁴ and Lihua Shi³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: : Epigenetic changes have been described in systemic lupus erythematosus (SLE) and offer a potential explanation for the chronicity of disease. We previously found…
Abstract Number: 1755 • 2015 ACR/ARHP Annual Meeting
The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus
John D. Mountz¹, Jun Li², Jennie Hamilton³, PingAr Yang⁴, Qi Wu⁵, Bao Luo⁶, Yanna Ding³, Hao Li⁶, David Crossman⁷, Erik Malarkey⁸, Yong Zhou², Yang-Xin Fu⁹ and Hui-Chen Hsu⁵, ¹Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁸Cell, Development, and Integrated Biology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Pathology, The University of Chicago, Chicago, IL
Background/Purpose: Marginal zone macrophages (MZMs) of the spleen are essential for rapid and tolerogenic clearance of apoptotic cells (ACs). MZMs are decreased in two…
Abstract Number: 2081 • 2015 ACR/ARHP Annual Meeting
The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program
Melissa T. Flores¹, Roberta Horton¹, Jillian A. Rose¹, Stephen A. Paget² and Michael Lockshin³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: An evaluation was conducted of a monthly hospital-based psychoeducational support group, ongoing since 1985, for people with lupus. Each 2-hour session begins with a…
Abstract Number: 401 • 2015 ACR/ARHP Annual Meeting
Racial and Ethnic Disparities in Depression Diagnosis and Treatment for Adolescents with SLE: Analysis of a National Medicaid Sample
Andrea Knight¹, Ming Xie² and David Mandell³, ¹Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Center for Mental Health Policy and Services Research, Philadelphia, PA, ³Psychiatry and Pediatrics, University of Pennsylvania, Center for Mental Health Policy and Services Research, Philadelphia, PA
Background/Purpose: Adolescents with systemic lupus erythematosus (SLE) are at high risk for depression. Racial/ethnic minorities are disproportionately affected by SLE, and previous studies suggest a…
Abstract Number: 806 • 2015 ACR/ARHP Annual Meeting
STAT1 Activation Promotes TLR8 Overexpression and Facilitates Mirokine Signaling Via Exosomes Containing a Mir-21 Endogenous Ligand: A Novel Innate Inflammatory Pathway in Systemic Lupus Erythematosus
Giancarlo R. Valiente^1,2, Nicholas A. Young², Lai-Chu Wu^3,4, Jeffrey Hampton⁵, Mary Severin⁶, Amy Lovett-Racke⁶ and Wael N. Jarjour⁷, ¹Medical Scientist Training Program, The Ohio State University College of Medicine, Columbus, OH, ²Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, ⁵Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, ⁷Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: The adaptive arm of the immune system plays a significant role in the pathophysiology of Systemic Lupus Erythematosus (SLE). However, recent studies suggest that…
Abstract Number: 1764 • 2015 ACR/ARHP Annual Meeting
Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1
Clayton Sontheimer¹ and Keith B. Elkon², ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions show local Type 1 Interferon (IFN-I) profiles similar…
Abstract Number: 2083 • 2015 ACR/ARHP Annual Meeting
Predictors of Health Perceptions Among Women with Lupus
Patricia P. Katz¹, Eliza Chakravarty², Robert S. Katz³ and Kaleb Michaud⁴, ¹Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Rush University Medical Center, Chicago, IL, ⁴Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Health perceptions, such as self-rated health, have been shown to predict multiple adverse health outcomes and to have a strong socioeconomic status (SES) gradient. …
Abstract Number: 402 • 2015 ACR/ARHP Annual Meeting
Predicting Area Under the Curve of Mycophenolate Mofetil in Childhood-Onset Systemic Lupus Erythematosus
Roberto Ezequiel Borgia¹, Masanobu Takeuchi², Deborah M. Levy³, Shinya Ito‎⁴ and Earl Silverman⁵, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Program of Physiology & Experimental Medicine, Peter Gilgan Centre For Research and Learning (PGCRL), The Hospital for Sick Children, Toronto ON, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴3Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children Toronto ON, Toronto, ON, Canada, ⁵Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Mycophenolate mofetil (MMF) is an immunosuppressive drug used off-label for the treatment of childhood-onset systemic lupus erythematosus (cSLE). Therapeutic drug monitoring (TDM) of MMF’s…
Abstract Number: 814 • 2015 ACR/ARHP Annual Meeting
Lupus Drives Atherosclerosis through CD4+CXCR3+ T Cells and Plasmacytoid Dendritic Cells
Tiphaine Goulenok¹, Marc Clement², Nicolas Charles³, Brigitte Escoubet⁴, Marie-Paule Chauveheid⁵, Thomas Papo⁶ and Karim Sacre⁷, ¹University Paris Diderot - APHP - Bichat Hospital, aris, France, ²University Paris Diderot - INSERM U1148, Paris, France, ³INSERM U699, Paris, France, ⁴University Paris- Diderot - APHP - Hôpital Bichat, Paris, France, ⁵Internal Medicine, Bichat-Claude Bernard Hospital, University Paris-7, Paris, France, ⁶CHU Bichat, Paris, France, ⁷Internal Medicine, University Paris-7, INSERM U1149, APHP, Bichat Hospital, Paris, France
Background/Purpose: Accelerated atherosclerosis is the leading cause of death in systemic lupus erythematosus (SLE). How SLE promotes accelerated atherosclerosis remains elusive. The purpose of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].